NCT07432373

Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection

Comparative Analysis of Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection (ALTON-PI)

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 80 (estimated)
• Sponsor: National University of Malaysia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Pneumonia, thought to be the chief aetiological process in the development of pleural space infection, is defined as an infection of the lung parenchyma with an estimated annual incidence rate of 5-11 cases per 1000 population, with around 50,000 hospital admissions in the U.K. per year. Parapneumonic effusions caused by an infection of the pleural membranes occur in 40-57% of cases of pneumonia. A variable percentage (10-20%) of parapneumonic effusions progresses to empyema (pus) and/or abscess formation (encapsulation). Pleural infection is associated with significant morbidity and mortality, which may be as high as 20-35% in immunocompromised patients. Standard treatment of these collections in adults involves antibiotic therapy, adequate drainage of infected fluid, and surgical intervention if conservative management fails. Appropriate treatment is adequate drainage via an intercostal catheter (ICC) with antibiotic therapy for parapneumonic effusions requiring clearance. Frequently, simple ICC drainage is ineffective due to the presence of loculations, formed predominantly by fibrinous material deposited in the fibrinopurulent phase of empyema, preventing free drainage of infected pleural fluid. The presence of fibrinous septae in the pleural space, known as loculations, may result in inadequate drainage of effusions and, therefore, nonresolution of infection and systemic sepsis. Surgical intervention (VATS or open) is usually required to clear loculations and resolve infection without adequate intercostal catheter drainage. Although the success rate of surgical intervention remains high, the morbidity and mortality of both VATS and open thoracotomy are of concern, particularly in a cohort of patients who may be older and with significant comorbidity. Less invasive therapies, which promote pleural space drainage and effective resolution of pleural infection, are therefore likely to be of considerable clinical utility. The MIST 2 trial has established intrapleural therapy as the mainstay of CPEE treatment, hence avoiding surgery and decreasing the length of hospitalization; however, little is known about the correct dosage needed for tPA and Dornase Alfa/Deoxyribonuclease (DNase). Dose and duration of intrapleural therapy based on MIST 2 involve multiple dosing and can be time-consuming for health care providers. Nevertheless, treatment of pleural infection with fibrinolytic therapy has been incorporated in the British Thoracic Society guideline 2023. Another study in 2022 by Cheong et al. used a modified regimen of intrapleural alteplase 16 mg t-PA with 5 mg DNase for three doses administered sequentially within 24 h. In this study, a modified regimen of t-PA and DNase offers an alternative therapeutic option for patients who are unfit or refuse surgical intervention but have persistent pleural infection. They have demonstrated similar treatment success comparable to other studies, as evidenced by improved pleural fluid drainage and reduced pleural opacity on day 7 chest x-ray, approximately 50% from the baseline. The mechanism of action of t-PA and DNase in the pleural cavity remains unclear. Studies suggested that IPFT may trigger the monocyte chemoattractant protein 1 (MCP-1) pathway, which promotes pleural fluid formation and subsequently causes a therapeutic lavage effect that increases pleural fluid drainage.

Detailed description

Research Questions: • Is there a difference in efficacy and safety between a combination of intrapleural alteplase (5 mg + tacholiquin, with intrapleural alteplase 5mg and DNase (Pulmozyme) 5mg in managing pleural infection? Primary Objective: • To compare the reduction of pleural opacity (in percentage) on chest radiograph from baseline (0-24 hours pre-intervention) to day 7 post-intervention between group A (alteplase + DNase) and group B (alteplase + tacholiquin) Secondary Objectives: * To compare the absolute and percentage change in inflammatory markers (WBC/CRP) from baseline (0-24 hours pre-intervention) to day 7 between the two groups * To compare the volume of pleural effusion drainage (in mL) 72 hours following post-intervention between the two groups * To compare the outcome between the two groups: * Length of hospital stay (in days) after the intervention for each group * The need for surgical intervention within 30 days * Adverse effects following alteplase/DNase and talteplase +Tacholiquin * Mortality rate at 30 days Study Hypothesis * The mean reduction in pleural opacity (%) from baseline (0-24 h pre-intervention) to day 7 is the same in both groups. * The mean change in WBC/CRP from baseline to day 7 is the same in both groups. * The mean pleural effusion drainage volume in both groups over the first 72 hours post-intervention is the same. * The mean length of hospital stay (days) post-intervention is the same in both groups. * The proportion requiring surgical intervention within 30 days is the same in both groups. * The proportion experiencing adverse effects is the same in both groups. * The 30-day mortality proportion is the same in both groups. Study Design Retrospective, observational cohort; on patients with pleural infection exposure defined by intrapleural regimen received (Alteplase+DNase vs Alteplase+Tyloxapol) DNase from June 2023 to June 2025 in HCTM UKM and University Malaya Medical Centre. Study Population Adult patients with pleural infection (complex pleural effusion or empyema) with poor outflow (≤ 150 cc) from chest drain after 24 Hours of insertion in medical and non-medical wards, HCTM UKM, and UMMC from June 2023 to June 2025. Sample Size and Power of Study Following the guidance of the UH Bristol and Weston Clinical Audit Team (Version 5), a pragmatic snapshot sample of 40 cases for each arm was deemed sufficient to measure current practice against the pre-defined standard, prioritizing feasibility over formal statistical representativeness.

Conditions

• Pleural Infection

Interventions

Type	Name	Description
DRUG	Intrapleural t-PA/Dnase arm	t-PA (Alteplase) 5-10mg and DNase (Pulmozyme)5mg t-PA (Alteplase) that is available in our pharmacy is 50mg ampoule and DNase (Pulmozyme) is 2.5mg per ampoule The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5-10mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium. Both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.
DRUG	t-PA (Alteplase) 5-10mg and Tyloxapol 200mg	t-PA (Alteplase) that is available in our pharmacy is 50mg ampoule and Tyloxapol 200mg. The number of installation of intrapleural t-PA/Tyloxapol depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5-10mg of Alteplase (t-PA) and 200mg Tyloxapol are diluted in each 50ml of 0.9% sodium. Both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for Tyloxapol. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.

Timeline

• Start date: 2026-04-01
• Primary completion: 2028-06-01
• Completion: 2028-07-01
• First posted: 2026-02-25
• Last updated: 2026-03-02

Locations

1 site across 1 country: Malaysia